Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
12/05/2025 15:08
Lexeo Therapeutics Inc LXEO.OQ reported a quarterly adjusted loss of 99 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -77 cents. The mean expectation of seven analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -83 cents to -69 cents per share. Reported revenue was zero; analysts expected zero. Lexeo Therapeutics Inc's reported EPS for the quarter was a loss of 99 cents. The company reported a quarterly loss of $32.66 million. Lexeo Therapeutics Inc shares had fallen by 22.5% this quarter and lost 59.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 1.5% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Lexeo Therapeutics Inc is $21.00 This summary was machine generated from LSEG data May 12 at 02:08 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.78 | -0.99 | Missed |
| Dec. 31 2024 | -0.81 | -0.78 | Beat |
| Sep. 30 2024 | -0.68 | -0.89 | Missed |
| Jun. 30 2024 | -0.69 | -0.64 | Beat |
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease